ADME of antibody-maytansinoid conjugates

AAPS Journal

Volumn 14, Issue 4, 2012, Pages 799-805

  Erickson, Hans K ^a   Lambert, John M ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

Antibody drug conjugate; Cancer; Maytansinoid

Indexed keywords

LORVOTUZUMAB MERTANSINE; MAYTANSINE; MONOCLONAL ANTIBODY; SAR 3419; TRASTUZUMAB EMTANSINE; TUBULIN; UNCLASSIFIED DRUG;

CANCER LOCALIZATION; CANCER THERAPY; CANCER TISSUE; CELL CYCLE ARREST; CELL KILLING; CROSS REACTION; DRUG ABSORPTION; DRUG ACTIVATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISOTOPE LABELING; LIVER PARENCHYMA; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE ASSEMBLY; NONHUMAN; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; MAYTANSINE; MICE; NEOPLASMS; TISSUE DISTRIBUTION; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869137056     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9386-x     Document Type: Review

References (52)

1. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
2. Lambert JM. Antibody-maytansinoid conjugates; a new strategy for the treatment of cancer. Drugs Future 2010; 35(6): 471
3. Chanan-Khan A, W. J, Gharibo M, Jagannath S, Munshi N, Anderson KC, DePaolo D, Lee K, Miller KC, Guild R, et al. Phase 1 Study of IMGN901, used as a monotherapy, in patients with heavily pre-Treated CD56-positive multiple myeloma. A preliminary safety and efficacy analysis. Blood (Ash Annual Meeting Abstracts) abstract 2283. 2009.
4. Fossella F, W. P, Lorigan P, Tolcher A, O'Brien M, O'Keeffe J, Zildjian S, Qin A, O'Leary J, Villalona-Calero M. Investigation of IMGN901 in CD56+ solid tumors: results from a phase I/II trial (study 001) and a phase I trial (study 002). 13th World Conference on Lung Cancer. 2009.
5. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol. 2005;5:543-9.
6. Younes A, G. L, Kim S, Romaguera J, Copeland AR, deCastro Farial S, Kwak L, Fayad L, Hagemeister F, Fanale M, et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by IV infusion every 3 weeks to patients with relapsed/refractory B-cell NHL. Blood (Ash Annual Meeting Abstracts) abstract 585. 2009.
7. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, YuW, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698-704.
8. Bai R, Friedman SJ, Pettit GR, Hamel E. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol. 1992;43:2637-45.
9. Singh R, Erickson HK. Antibody-cytotoxic agent conjugates: preparation and characterization.Methods Mol Biol. 2009;525:445-67. xiv
10. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347-56.
11. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem. 2011;22:717-27.
12. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blattler WA, Chari RV. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006;49:4392-408.
13. Girish S, GuptaM,Wang B, LuD,Krop IE,Vogel CL, Burris Iii HA, Lorusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012;69 (5):1229-40.
14. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011;17:6437-47.
15. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C,Maes K, Chari RV, Lambert JM, Rowinsky EK. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol. 2003;21:211-22.
16. Xie H, Blattler WA. In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Expert Opin Biol Ther. 2006;6:281-91.
17. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX. Engineered thiotrastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16:4769-78.
18. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-90.
19. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA. Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66:4426-33.
20. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Audette CA, Gupta M, Pinkas J, Tibbitts J. The effect of different linkers on target cell catabolism and pharmacokinetics/ pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012;11(5):1133-42.
21. Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A. Anti-CD22-MCCDM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem. 2008;19:1673-83.
22. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, Senter PD. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19:759-65.
23. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF,Mai E, Li D, Tibbitts J, Baudys J, Saad OM, Scales SJ, McDonald PJ, Hass PE, Eigenbrot C, Nguyen T, SolisWA, Fuji RN, Flagella KM, Patel D, Spencer SD, Khawli LA, Ebens A,WongWL, Vandlen R, Kaur S, SliwkowskiMX, Scheller RH, Polakis P, Junutula Jr. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30: 184-9.
24. Fishkin N, Maloney EK, Chari RV, Singh R. A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. Chem Commun (Camb). 2011;47:10752-4.
25. Baldwin AD, Kiick KL. Tunable degradation of maleimide-Thiol adducts in reducing environments. Bioconjug Chem. 2011;22:1946-53.
26. Xie H, Audette C, Hoffee M, Lambert JM, Blattler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther. 2004;308:1073-82.
27. Mayo F, X. H, Erickson H, Wunderli P, Garrett L, Whitman K, Leece B, Lutz RJ. Pharmacokinetics and Biodistribution of huC242-DM4, an Antibody- Maytansinoid Conjugate That Tartgets CanAg-Postive Tumors, In AACR Meeting. 2005.
28. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem. 2011;22:1994-2004.
29. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063-70.
30. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, Erickson H. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem. 2011;22:728-35.
31. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, Lorusso PM, Girish S. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine T-DM1: an emphasis on preclinical and clinical catabolism. Curr Drug Metab. 2012 (in press)
32. Alley SC, Zhang X,Okeley NM,Anderson M, Law CL, Senter PD, Benjamin DR. The pharmacologic basis for antibody-Auristatin conjugate activity. J Pharmacol Exp Ther. 2009;330:932-8.
33. Wright A, Sato Y, Okada T, Chang K, Endo T, Morrison S. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology. 2000;10:1347-55.
34. Issell BF, Crooke ST.Maytansine. Cancer Treat Rev. 1978;5:199-207.
35. Chanan-Khan A, J. S, Heffner T, Avigan D, Lee K, Lutz RJ, Haeder T, Ruehle M, Uherek C, Wartenberg-Demand A, et al. Phase I Study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. Blood (Ash Annual Meeting Abstracts) abstract 1862. 2009.
36. Smith SV. Technology evaluation: huN901-DM1, ImmunoGen. Curr Opin Mol Ther. 2005;7:394-401.
37. Younes A, F-T A, Bartlett NL, Leonard JP, Lynch C, Kennedy DA, Sievers EL. Multiple complete responses in a Phase 1 doseescalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood (Ash Annual Meeting Abstracts) abstract 2731. 2008.
38. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blattler WA, Goldmacher VS. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66:3214-21.
39. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng. 1999;1:241-63.
40. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421-34.
41. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther. 2004;3:1493-501.
42. Sedlacek H-H, Seeman G, Hoffman D, Czech J, Lorenz P, Kolar C, Bosslet K. Antibodies as carriers of cytotoxicity, vol. 43. Marburg: Karger; 1992.
43. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, Chen X. Quantitative radioimmunoPET imaging of EphA2 in tumorbearing mice. Eur J Nucl Med Mol Imaging. 2007;34:2024-36.
44. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPAtrastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging. 2009;36:81-93.
45. Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007;255:232-40.
46. Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52:5144-53.
47. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, Goldenberg DM. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother. 1991;33:351-8.
48. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res. 2008;14:2171-9.
49. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM. SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011;17:6448-58.
50. Sun X, C. L, Ellis M, Whiteman KR, Pinkas J, Lazar A, Erickson H. Lorvotuzumab mertansine displays favorable pharmacokinetics and tumor delivery in mouse models. AACR-NCI-EORTC Abstract # B195. 2011.
51. Erickson HK, P. C, Mayo MF, Widdison WC, Audette C, et al. Target-cell processing of the anti-CD19 antibody maytansinoid conjugate SAR3419 in preclinical models. AACR Abstract 5473. 2009.
52. Erickson HK, M. M, Widdison W, Audette C, Kovtun Y, Chari R, Lutz RJ, Singh R. Linker selection in antibody-maytansinoid conjugates impacts bystander killing in tumor xenograft mouse models. AACR-NCI-EORTC abstract #A86. 2007.